Exposure to COVID-19 virus-like particles modulates firing patterns of cortical neurons in the mouse brain.

Publication date: Jul 03, 2025

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes a systemic infection that affects the central nervous system. However, its high infectivity makes comprehensive research with the active virus challenging. Here, we use virus-like particles (VLPs) to explore how exposure to SARS-CoV-2 proteins affects brain activity patterns in wild-type mice and in mice that express the human tau protein. VLP exposure elicits changes in corticosterone and distinct chemokine levels. Longitudinal two-photon microscopy recordings in primary somatosensory and motor cortices reveal substantial short-term increases in cortical activity in VLP-injected mice, with increased stimulus-evoked activity in both genotypes and elevated spontaneous activity in the human tau genotype only. Vehicle-injected human tau mice also show increases in cortical activity patterns. Over the following weeks, activity metrics partially subside but do not completely return to baseline levels. Overall, our data suggest that exposure to SARS-CoV-2 VLPs leads to strong short-term disruption of cortical activity patterns in mice with long-term residual effects. Middle-aged human tau mice, which have a more vulnerable genetic background and overexpression of the tau protein, exhibit more severe pathobiology and may be at risk for more adverse outcomes.

Open Access PDF

Concepts Keywords
Coronavirus Animals
Mice Brain
Nervous Cerebral Cortex
Pathobiology COVID-19
Weeks Female
Humans
Male
MAPT protein, human
Mice
Mice, Transgenic
Neurons
SARS-CoV-2
tau Proteins
tau Proteins

Semantics

Type Source Name
disease MESH COVID-19
disease MESH causes
disease MESH infection
disease IDO infectivity
drug DRUGBANK Corticosterone
drug DRUGBANK Pumactant
disease MESH Severe Acute Respiratory Syndrome
disease MESH cognitive decline
disease MESH neurodegenerative disorders
disease MESH complications
disease IDO host
disease IDO facility
disease IDO blood
pathway REACTOME Immune System
drug DRUGBANK Trestolone
disease IDO protein
drug DRUGBANK Cefaclor
drug DRUGBANK Proline
disease IDO susceptibility
disease MESH sti
drug DRUGBANK Coenzyme M
disease MESH tauopathy
disease MESH anxiety
drug DRUGBANK Cysteamine
disease MESH long COVID
disease MESH inflammation
disease IDO reagent
drug DRUGBANK Sorbitol
drug DRUGBANK Phosphate ion
drug DRUGBANK Edetic Acid
drug DRUGBANK Sodium lauryl sulfate
disease IDO assay
drug DRUGBANK Water
drug DRUGBANK Isoflurane
drug DRUGBANK Ranitidine
disease MESH weight loss
disease MESH posture
disease IDO quality

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *